Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-directed neoadjuvant chemotherapy with or without radiotherapy for oesophageal or OG junction adenocarcinoma
ACTRN12609000665235Phase 2Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Jul 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cisplatin, fluorouracil and docetaxel in adenocarcinoma of the lower esophagus and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Histological response to neoadjuvant therapy. Started Jul 2009; status: completed.
02
Drugs
cisplatinfluorouracildocetaxel
03
Conditions
adenocarcinoma of the lower esophagusgastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ACTRN12609000665235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000665235.